首页> 外文OA文献 >Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

【2h】

Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

机译：一种老年韩国患者的人类疱疹病毒8-无关的初级活力淋巴瘤，具有良好的Rituximab加环磷酰胺，多柔比星，长春螯合物和泼尼松龙

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Junghoon Shin; Jeong-Ok Lee; Ji-Young Choe; Soo-Mee Bang; Jong-Seok Lee;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT] (NHL-14) [J] . Fridrik Michael A., Jaeger Ulrich, Petzer Andreas, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：与利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙相比，利妥昔单抗，环磷酰胺，非聚乙二醇脂质体阿霉素，长春新碱和泼尼松龙在前线治疗弥漫性大B细胞淋巴瘤患者中的心脏毒性来自奥地利癌症药物的一项随机III期研究治疗工作组[Arbeitsgemeinschaft Medikamentose肿瘤治疗AGMT]（NHL-14）
2. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: A prospective study by the Finnish Lymphoma Group [J] . R?tyR., HonkanenT., JantunenE., Leukemia and lymphoma . 2012,第10期

机译：利妥昔单抗，阿糖胞苷和氟达拉滨联合环磷酰胺，阿霉素，长春新碱和泼尼松龙的长期免疫化学疗法，然后对未治疗的老年套细胞淋巴瘤患者进行利妥昔单抗维持治疗：芬兰淋巴瘤小组的一项前瞻性研究
3. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma [J] . Kayamori Kensuke, Shono Katsuhiro, Onoda Masahiro, Hematology. . 2019,第1期

机译：利妥昔单抗和减少剂量环磷酰胺，多柔比星，长春酮和泼尼松治疗弥漫性大B细胞淋巴瘤的疗效和耐受性
4. DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CANINE LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED STUDY [C] . Janet Lori, Timothy Stein, Douglas Thamm Annual Conference of the Veterinary Cancer Society . 2009

机译：多柔比星和环磷酰胺治疗犬淋巴瘤：随机，安慰剂对照研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide Doxorubicin Vincristine and Prednisolone [O] . Junghoon Shin, Jeong-Ok Lee, Ji-Young Choe, 2017

机译：人类疱疹病毒8 –无关的原发性淋巴瘤–老年韩国患者对利妥昔单抗加环磷酰胺阿霉素长春新碱和泼尼松龙反应良好
7. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial [O] . Luis Fayad, Stephen M. Ansell, Ranjana Advani, 2015

机译：DACETUZUMAB加里康妥昔单抗，IFOSFAMIDE，CARBOPLATIN和ETOPOSIDE作为弥漫性大型B细胞淋巴瘤患者的救助治疗，RITUXIMAB，环磷酰胺，多码霉素，长春碱和泼尼松酮：随机，双盲，安慰剂控制相2B试验

Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

著录项

相似文献

相关主题

期刊订阅